GITR Ligand Rat anti-Mouse, BUV395, Clone: MIH44, BD Optibuild™
Rat Monoclonal Antibody
Manufacturer: BD Biosciences 742581
The MIH44 monoclonal antibody specifically binds to Glucocorticoid-induced TNF-related Ligand (GITR Ligand). The GITR Ligand protein is encoded by the Tnfsf18 /( Tumor necrosis factor ligand superfamily member 18 /) gene. The GITR Ligand is a type II transmembrane protein that is expressed on endothelial cells and antigen presenting cells, including B cells, macrophage and dendritic cells. The GITR Ligand reportedly costimulates T cell activation and reverses CD4+CD25+ Treg cell-mediated suppression by interaction with its cognate receptor, GITR that is expressed by these cells.The antibody was conjugated to BD Horizon™ BUV395 which is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This dye has been exclusively developed by BD Biosciences to have minimal spillover into other detectors, making it an optimal choice for multicolor flow cytometry. With an Ex Max at 348 nm and an Em Max at 395 nm, BD Horizon BUV395 can be excited with a 355 nm laser and detected with a 379/28 filter. BUV395 is a UV-excitable dye that has been developed exclusively by BD Biosciences. With an excitation max of 348 nm and emission max of 395 nm, BUV395 can be excited by the 355nm laser and detected in a 379/28 filter. This dye is optimal for multicolor flow cytometry because it has little to no spillover into other detectors.
|Brilliant Ultraviolet 395|
|Tnfsf18, Gitrl,Glucocorticoid-induced-tumor necrosis factor receptor ligand|
|GITRL/GFP-transfected L cells|
|Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.|
|Aqueous buffered solution containing ≤0.09% sodium azide.|
|Rat IgG2b κ|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok